Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.387 estudios en Cancer (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. A Prospective Ocular Tumor Study Rochester, Minn. The purpose of this study is to use clinical, imaging, molecular, and epidemiological investigation toward the goal of providing new knowledge about ocular tumors that will be useful in understanding, diagnosing, monitoring, and suggesting new avenues of treatment. This study does not involve experimental treatment of any ocular tumor, but rather observation of tumor natural history or outcomes following standard of care therapy, associated systemic and ocular conditions, and basic research investigations to better understand tumor biomarkers and pathophysiology. A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and tolerability of BMF-500 and to determine the OBD and RP2D of BMF-500. Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors Rochester, Minn. The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors. The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood. A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) Jacksonville, Fla. The purpose of phase 2a is to establish proof-of-concept (POC) for AG-946 in participants with lower-risk myelodysplastic syndromes (LR-MDS) and to evaluate the safety, effect, and pharmacokineticsof AG-946 on additional measures of anemia. Additionally to evaluate the effect of AG-946 on transfusion burden (participants with LTB only) and the effect of AG-946 on pharmacodynamic biomarkers. The purpose of phase 2b is to compare the effect of AG-946 versus placebo and to detect a doseresponse for erythroid response in participants with LR-MD A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma Rochester, Minn., La Crosse, Wis. The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients. Blood And Urine Identification Of Methylated DNA Markers In Invasive Bladder Carcinoma Rochester, Minn. The purpose of this study is to, in tissue, discover and validate DNA methylation markers (MDMs) for detection of invasive urothelial carcinoma of the bladder. In blood, to assess the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder. In urine, to explore the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder. Diagnostic accuracy on urine can be compared with that on plasma using paired samples. A Feasibility Study To Evaluate The Safety Of The TheraSphere Glioblastoma (GBM) Device In Patients With Recurrent GBM Jacksonville, Fla. The purpose of this study is to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent glioblastoma (GBM). Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 3737 Ir a página 3838 Ir a página 3939 Profesionales médicos Cancer clinical-trials